NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Tuesday closed up +0.03%, the Dow Jones Industrials Index ($DOWI) (DIA) closed up +0.28%, and the Nasdaq 100 Index ($IUXX) ...

This was the stock's third consecutive day of losses.

With many biotechs and pharmas needing to fill impending revenue holes coming later in the decade, M&A is posed to pick up, but not until government and regulatory uncertainty settles down. Dealmaking ...

Stocks wavered–while bond yields rose across the board definitively–ahead of tomorrow’s inflation report. The indexes started the day with losses, and wavered after Fed Chair Jerome Powell told ...

CytomX Therapeutics Inc . (NASDAQ:CTMX) stock has reached a new 52-week low, trading at $0.76, as the biopharmaceutical company faces a challenging market environment. Despite the recent decline, ...

The S&P 500 Index ($SPX) (SPY) today is down -0.02%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.06%, and the ...

Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...

SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), currently valued at approximately $5 billion in market capitalization, has announced the appointment of Robert E. Landry to its Board ...